Ab­b­Vie set­tles one of its fi­nal Hu­mi­ra biosim­i­lar suits for an­oth­er mid-2023 de­layed en­try

Ab­b­Vie’s block­buster rheuma­toid arthri­tis drug Hu­mi­ra will see even more com­pe­ti­tion next year, as Ab­b­Vie and biosim­i­lar de­vel­op­er Alvotech set­tled a court dis­pute over when the com­pa­ny’s adal­i­mum­ab biosim­i­lar can launch, even as the drug has yet to be ap­proved by the FDA.

The set­tle­ment ful­ly re­solves all pend­ing le­gal US dis­putes be­tween Ab­b­Vie and Alvotech re­lat­ed to the biosim­i­lar, which re­moves any bar­ri­ers block­ing Alvotech’s high-con­cen­tra­tion ver­sion of adal­i­mum­ab from reach­ing US pa­tients on Ju­ly 1, 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER